Loading...
XNAS
LRMR
Market cap316mUSD
Dec 05, Last price  
3.70USD
1D
0.54%
1Q
-6.09%
Jan 2017
16.35%
IPO
-81.31%
Name

Larimar Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LRMR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
81.45%
Rev. gr., 5y
%
Revenues
0k
Net income
-81m
L+118.15%
-36,570,000-74,286,000-57,878,000-52,028,000-61,368,000-23,132,000-42,327,000-50,310,000-34,184,000-36,949,000-80,604,000
CFO
-71m
L+111.48%
-28,241,000-59,554,000-51,975,000-43,784,000-51,487,000-22,699,000-42,199,000-42,105,000-27,569,000-33,459,000-70,760,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
URL
https://larimartx.com/
IPO date
Jun 19, 2014
Employees
26
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT